Keywords: USA, FDA, Bristol-Myers, Sprycel, Sunovio, Katuda, Dainnippon Sumitomi, Vivus, Qnexa

US FDA approves additional medical indication for Bristol-Myers Squibb’s Sprycel; clears Sunovion’s Latuda; further delays Vivus’ Qnexa

Article | 29 October 2010

Print This

The US Food and Drug Administration yesterday approved a new indication for drug major Bristol-Myers Squibb’s (NYSE: BMY) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in